Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Feld

Showing results (341-350 of 451) with videos related to

Pageof 46
Sort By:
Nature Reviews. Gastroenterology & Hepatology|February 5, 2025
New potent HBV replication inhibitors for the management of chronic hepatitis B are neededTimothy M Block, Ju-Tao Guo, Fabien Zoulim, et al.
Canadian Journal of Gastroenterology & Hepatology|October 15, 2014
The 3rd Canadian Symposium on Hepatitis C Virus: expanding care in the interferon-free eraSonya A MacParland, Marc Bilodeau, Jason Grebely, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 22, 2016
Effectiveness and Safety of Sofosbuvir-Based Regimens for Chronic HCV Genotype 3 Infection: Results of the HCV-TARGET StudyJordan J Feld, Raoel Maan, Stefan Zeuzem, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 11, 2019
HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype DefinitionWillem P Brouwer, Qian Zhao, Bettina E Hansen, et al.
Journal of Viral Hepatitis|November 8, 2017
Intrapatient viral diversity and treatment outcome in patients with genotype 3a hepatitis C virus infection on sofosbuvir-containing regimensN Bhardwaj, M Ragonnet-Cronin, B Murrell, et al.
Canadian Liver Journal|July 28, 2023
Public reimbursement policies in Canada for direct-acting antiviral treatment of hepatitis C virus infection: A descriptive studyGaelen Snell, Alison D Marshall, Jennifer van Gennip, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 9, 2020
Hepatitis B Virus RNA as Early Predictor for Response to Pegylated Interferon Alpha in HBeAg-Negative Chronic Hepatitis BMina S Farag, Margo J H van Campenhout, Maria Pfefferkorn, et al.
Canadian Liver Journal|September 22, 2022
Birth cohort hepatitis C antibody prevalence in real-world screening settings in OntarioMia J Biondi, Grishma Hirode, Camelia Capraru, et al.
Journal of Hepatology|November 26, 2020
Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severityLisette A P Krassenburg, Raoel Maan, Alnoor Ramji, et al.
Advances in Therapy|May 22, 2021
Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World CohortsXavier Forns, Jordan J Feld, Douglas E Dylla, et al.
Pageof 46

Showing results (341-350 of 451) with videos related to

Sort By:
Pageof 46
Nature Reviews. Gastroenterology & Hepatology|February 5, 2025
New potent HBV replication inhibitors for the management of chronic hepatitis B are neededTimothy M Block, Ju-Tao Guo, Fabien Zoulim, et al.
Canadian Journal of Gastroenterology & Hepatology|October 15, 2014
The 3rd Canadian Symposium on Hepatitis C Virus: expanding care in the interferon-free eraSonya A MacParland, Marc Bilodeau, Jason Grebely, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 22, 2016
Effectiveness and Safety of Sofosbuvir-Based Regimens for Chronic HCV Genotype 3 Infection: Results of the HCV-TARGET StudyJordan J Feld, Raoel Maan, Stefan Zeuzem, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 11, 2019
HBV Genotype-Specific Levels of Hepatitis B Surface Antigen Improve HBV Phenotype DefinitionWillem P Brouwer, Qian Zhao, Bettina E Hansen, et al.
Journal of Viral Hepatitis|November 8, 2017
Intrapatient viral diversity and treatment outcome in patients with genotype 3a hepatitis C virus infection on sofosbuvir-containing regimensN Bhardwaj, M Ragonnet-Cronin, B Murrell, et al.
Canadian Liver Journal|July 28, 2023
Public reimbursement policies in Canada for direct-acting antiviral treatment of hepatitis C virus infection: A descriptive studyGaelen Snell, Alison D Marshall, Jennifer van Gennip, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 9, 2020
Hepatitis B Virus RNA as Early Predictor for Response to Pegylated Interferon Alpha in HBeAg-Negative Chronic Hepatitis BMina S Farag, Margo J H van Campenhout, Maria Pfefferkorn, et al.
Canadian Liver Journal|September 22, 2022
Birth cohort hepatitis C antibody prevalence in real-world screening settings in OntarioMia J Biondi, Grishma Hirode, Camelia Capraru, et al.
Journal of Hepatology|November 26, 2020
Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severityLisette A P Krassenburg, Raoel Maan, Alnoor Ramji, et al.
Advances in Therapy|May 22, 2021
Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World CohortsXavier Forns, Jordan J Feld, Douglas E Dylla, et al.
Pageof 46